s6y

Akari Therapeutics Plc

Ticker
AKTX
CIK
1541157
Industry
Pharmaceutical Preparations
Formerly
Celsus Therapeutics Plc., Morria Biopharmaceuticals PLC

Financials 25

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. NT 10-Q Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB for period ending Mar 31, 2026
  5. 10-K Annual Report for period ending Dec 31, 2025
  6. 10-Q Quarterly Report for period ending Sep 30, 2025
  7. 10-Q Quarterly Report for period ending Jun 30, 2025
  8. 10-Q Quarterly Report for period ending Mar 31, 2025
  9. 10-K Annual Report for period ending Dec 31, 2024
  10. NT 10-K Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10-KT for period ending Dec 31, 2024

All 25 financials filings

News 66

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 66 news filings

Ownership 173

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 3 Initial statement of beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 173 ownership filings

Prospectus 67

  1. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  2. S-3/A Registration statement for specified transactions by certain issuers
  3. S-3/A Registration statement for specified transactions by certain issuers
  4. S-3 Registration statement for specified transactions by certain issuers
  5. S-1/A General form of registration statement for all companies including face-amount certificate companies
  6. RW Registration Withdrawal Request
  7. S-1 General form of registration statement for all companies including face-amount certificate companies
  8. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  9. S-1 General form of registration statement for all companies including face-amount certificate companies
  10. 424B5 Prospectus filed pursuant to Rule 424(b)(5)

All 67 prospectus filings

Proxies 25

  1. DEF 14A Definitive proxy statements
  2. DEF 14A Definitive proxy statements
  3. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  4. DEF 14A Definitive proxy statements
  5. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  6. DEF 14A Definitive proxy statements
  7. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  8. DEF 14A Definitive proxy statements
  9. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  10. DEF 14A Definitive proxy statements

All 25 proxies filings

Other 392

  1. SCHEDULE 13G/A
  2. SCHEDULE 13G/A
  3. SCHEDULE 13G
  4. SCHEDULE 13G
  5. EFFECT Notice of Effectiveness
  6. EFFECT Notice of Effectiveness
  7. SCHEDULE 13G
  8. D Exempt (Private) Offering
  9. EFFECT Notice of Effectiveness
  10. POS AM Post-effective amendment to a registration statement that is not immediately effective upon filing

All 392 other filings